CEL SCI Corp (CVM) stock
CVMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$1.19−0.12 (-9.16%)
Close on Nov 12, 2026Market cap $20.93MP/E –Yield –
Cel Sci ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Cel Sci's ebitda for the twelve months ending Jun 30, 2026 was -$20.29M. For fiscal 2025 it was -$22.75M. The highest annual figure on record is -$11.60M in fiscal 2009.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -$22.75M | – |
| FY2024 | Sep 30, 2024 | -$24.22M | – |
| FY2023 | Sep 30, 2023 | -$29.36M | – |
| FY2022 | Sep 30, 2022 | -$34.09M | – |
| FY2021 | Sep 30, 2021 | -$35.75M | – |
| FY2020 | Sep 30, 2020 | -$28.60M | – |
| FY2019 | Sep 30, 2019 | -$19.61M | – |
| FY2018 | Sep 30, 2018 | -$16.20M | – |
| FY2017 | Sep 30, 2017 | -$20.81M | – |
| FY2016 | Sep 30, 2016 | -$23.02M | – |
| FY2015 | Sep 30, 2015 | -$31.71M | – |
| FY2014 | Sep 30, 2014 | -$24.96M | – |
| FY2013 | Sep 30, 2013 | -$19.59M | – |
| FY2012 | Sep 30, 2012 | -$16.80M | – |
| FY2011 | Sep 30, 2011 | -$17.45M | – |
| FY2010 | Sep 30, 2010 | -$18.04M | – |
| FY2009 | Sep 30, 2009 | -$11.60M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$4.61M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$4.37M | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$4.40M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$6.90M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$4.53M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$5.42M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$5.90M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$6.96M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$5.69M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$6.09M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$5.48M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$8.31M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$7.20M | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$7.19M | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$6.66M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$9.82M | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$7.74M | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -$8.57M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$7.96M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$9.68M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$9.91M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -$7.98M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$8.18M | – |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$9.67M | – |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$6.42M | – |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$6.16M | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -$6.35M | – |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -$5.57M | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -$5.01M | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$4.15M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -$4.88M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$3.44M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$3.91M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$4.07M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$4.77M | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$3.69M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$4.60M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$7.75M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$4.78M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$6.51M | – |
See a number that looks wrong?